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Non-steroidal anti-inflammatory drugs (NSAIDs) interfere with
the growth of mammary tumours (Lala et al, 1997; Robertson et al,
1998) and prevent distant metastasis (Hubbard et al, 1988; Khoo 
et al, 1992) in rodents. The epidemiologic evidence for similar
effects in women is limited and inconsistent (Isomäki et al, 1978;
Friedman and Ury, 1980; Gridley et al, 1993; Thun et al, 1993;
Schreinemachers and Everson, 1994; Harris et al, 1995, 1996;
Egan et al, 1996).
To study the effects of NSAID use on breast cancer risk we
carried out a nested case–control study, using the records of the
Saskatchewan Cancer Agency (SCA) and data collected routinely
by the Saskatchewan Prescription Drug Plan (SPDP), which has
provided full or partial outpatient drug coverage to the
Saskatchewan population since 1975.
To study the effects of NSAID use on breast cancer growth and
spread we carried out analyses using the drug exposure histories of
the cases and attributes of the stage of their tumours at diagnosis,
as assessed by the international tumour–lymph node–metastasis
(TNM) system (Spiessl et al, 1992).
SUBJECTS AND METHODS
Study populations
The source population was the open population of women aged 
³ 35 years, eligible to receive benefits from the SPDP during 1981
to mid-1995 with no history of cancer since 1970 other than non-
melanoma skin cancer or cervical carcinoma in situ.
Subjects entered the source population on 1 January 1981, their
35th birthday, or on the date of immigration to Saskatchewan,
whichever occurred latest. Subjects left the source population on
30 June 1995, or on the date of diagnosis of breast cancer, death or
emigration, whichever occurred first.
The SPDP has provided coverage for outpatient prescription
drugs for 94% of the Saskatchewan population (1.01 million
people in mid-1991; Rawson et al, 1992). Excluded are aborigi-
nals, military personnel, members of the Royal Canadian Mounted
Police, and inmates of federal penitentiaries: they are covered by
federal agencies. The accuracy of the identifying and recorded
prescription information both exceed 99% (Risch and Howe,
1994).
The cases were subjects in the source population who were
diagnosed with histologically proven invasive female breast
cancer and reported to the SCA. Registration of cancer cases was
nearly complete (Parkin et al, 1997). To be in our study, cases must
have been eligible to benefit from the SPDP for ³ 5 years before
diagnosis. Hereafter, the date of diagnosis will be designated as the
‘index date’.
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DOI: 10.1054/ bjoc.2000.1119, available online at http://www.idealibrary.com on The potential controls for each case were the subjects in the
source population born within 1 year of the case, who were alive
when the case was diagnosed. From the sets of potential controls,
four cases were randomly selected. The date of diagnosis was
assigned to each of the matched controls as their index date.
Controls also must have been covered by the SPDP for ³ 5 years
before the index date.
Linkage methods
Information in the databases of the SPDP and the SCA was linked
electronically using personal health care identifiers (Rawson et al,
1992).
Drug exposure data
Drug exposure data were obtained from the SPDP database for the
period between the index date and 1 January 1976 or the coverage
initiation date, whichever was later. Drug exposure histories
ranged from 5 to 19.5 years in length.
The following data were extracted for each NSAID outpatient
prescription dispensed: the date, class and identity of the drug
(American Hospital Formulary System classification), number of
pills dispensed, and strength (mg per pill). The daily dose and
treatment duration were not available.
No data were available from 1 July 1987 to 31 December 1988,
because the SPDP did not record most of the dispensing of drugs
to individuals then (Rawson et al, 1992). The database also lacked
information on drugs dispensed during hospitalizations and as
samples from physicians.
Data on potential confounders
Information on potential confounders other than those recorded in
the SPDP database was obtained from telephone interviews of
selected subsamples of cases and controls with index dates
between 30 June 1991 and 30 June 1995 to maximize the number
of living subjects. If they died before the interview, we attempted
to interview a family member.
We employed a two-stage design (Cain and Breslow, 1988). To
make this phase of the study maximally informative, the stage 1
population was restricted to subjects aged 45–79 years on the
index date who were eligible to benefit from the SPDP for ³ 10
years. Subsamples, comprising the stage 2 subjects, were selected
from this population according to both disease and exposure status
to gain statistical efficiency and reduce cost.
Both unexposed subjects and those with high levels of NSAID
exposure were deliberately over-represented in stage 2. We
planned to interview roughly equal numbers (n » 150) in each of
the four disease/exposure categories: the ‘balanced design’.
The selection bias introduced by subsampling according to both
disease and exposure status was corrected in the analysis with the
known sampling fractions. This increased the precision of the
effect estimates, since the sampling fractions contained informa-
tion from stage 1 about the exposure–disease relationship (Cain
and Breslow, 1988).
The interviews were carried out using a questionnaire with high
levels of reliability (Sharpe, 1999). The interviewers were blinded
to the subjects’ disease and exposure status.
Ethical issues and confidentiality
Letters were mailed from the SCA starting in November 1996 to
obtain physicians’ consent to contact the selected cases or the
families of deceased cases: 78.6% consented. Letters were then
mailed from the SCA to cases requesting their informed written
consent to be interviewed. Non-responders were mailed a
reminder letter and another consent form. The families of deceased
cases were contacted by telephone prior to mailing to ask if they
would agree to receive a letter. Overall, 67.4% of the cases/fami-
lies consented.
The process of contacting controls, or their families, was carried
out concurrently in an identical way, except that the letters were
mailed from Saskatchewan Health without requesting a physi-
cian’s consent. Overall, 43.0% of the controls/families consented.
These response rates pertained to our attempts to obtain infor-
mation about potential confounders. We had already obtained
NSAID exposure data on all subjects from the SPDP database.
Response rates for exposed and unexposed subjects were very
similar.
Interviews proceeded concurrently from December 1996 to
April 1998. The mean interval from index date to interview was
3.7 years for cases (1.1 standard deviation (s.d.)) and 3.8 years for
controls (1.1 s.d.).
Extraction of data from the databases was carried out by
employees of the SCA and Saskatchewan Health. Interviews were
carried out by four interviewers employed by Saskatchewan
Health. The data delivered to the investigators for analysis
contained no nominal information. The study was approved by
ethics committees of the Cross Agency Study Committee of
Saskatchewan Health, the Internal Review Board of the SCA, and
the Sir Mortimer B Davis–Jewish General Hospital.
Statistical analysis
We analysed exposure to NSAIDs as a class on the assumption that
all NSAIDs would affect the risk of breast cancer similarly.
To study the effects of exposure timing we a priori divided time
preceding the index date into five successive periods: 1–6 months,
7–12 months, 2–5 years, 6–10 years and 11–15 years.
Exposure during each period was characterized as the average
rate of dispensing NSAIDs. The rate was based on the proportion
of the recommended maximum daily dose of each different
NSAID dispensed (pi = average mg day–1 dispensed 4 maximum
mg/day recommended for NSAIDi) during each period. The sum
of the proportions, i.e. Spi for all the NSAIDs dispensed during a
period, represented the measure of exposure. The usual maximum
daily dose for each drug was taken from the manufacturers’
recommendations (Krogh, 1995). The drugs and their recom-
mended maximum daily doses are tabulated elsewhere (Collet et
al, 1999, Table 1).
We did not quantify the duration of NSAID exposure because
we lacked information on the length of prescribed treatment. Since
NSAID use is often intermittent, we doubted the validity of esti-
mating duration of use.
If the drug exposure history for a period was missing or incom-
plete, due either to the date of the subject’s entry into the source
population or to the 1.5-year period of missing information, the
subject was assigned to a separate category designated ‘other’
(Breslow and Day, 1980).
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numbers of subjects in stages 1 and 2 with known levels of expo-
sure during the periods 2–5 and 6–10 years before the index date.
Accordingly, we used the information available to impute the level
of NSAID exposure. Exposure (Spi) was calculated by dividing the
amounts of NSAIDs known to have been dispensed during a period
by the number of days on which the drugs could have been
dispensed and recorded in the SPDP database. The mean numbers
of days for which exposure information was available were almost
identical for the two periods for the subjects in stages 1 and 2.
For analyses involving all subjects accrued from 1981 to 1995,
we calculated odds ratios (ORs) with 95% confidence intervals
(CIs) to estimate incidence density ratios (rate ratios (RRs)) using
conditional logistic regression applied to the age- and index-date-
matched case/control sets.
Because the stage 2 (interviewed) subjects were selected
according to both disease and exposure status, the original matched
sets were broken up. Accordingly, we calculated RRs and 95% CIs
with unconditional logistic regression with adjustment for age
using 5-year categories.
The statistical model used to relate the RRs to the drug exposure
history was: exp(b1–6 mosX1–6 mos+b7–12 mosX7–12 mos+b2–5 yrs  X2–5 yrs+
b6–10 yrs X6–10 yrs+b11–15 yrsX11–15 yrs) where the values of bi represented
the regression coefficients, and the values of Xi represented drug
exposure during the time periods. This approach followed
Miettinen’s view that exposures during ‘different time periods
represent separate determinants … mutually confounded and thus
requiring joint representation in the same model’ (Miettinen, 1985).
Within each period dosage was represented by a categorical
variable: unexposed (the referent), low (0<Spi≤0.1), medium
(0.1<Spi≤0.3), high (Spi>0.3), and ‘other’ (unknown).
The validity of the exposure imputation used for the stage 1 and
stage 2 data was assessed by simulating another 1.5-year gap in the
exposure record when exposures were known, of the same dura-
tion as the existing gap. The effects of the imputed exposures were
comparable to the effects of the known exposures (Sharpe,1999).
In most analyses testing for trends was carried out by repre-
senting the categories of exposure with ordinal variables, consid-
ered as continuous, and examining the significance of the
coefficients with a z-test. P-values for trend for the analyses of the
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Table 1 RRs of breast cancer according to NSAID exposure by time period before diagnosis, with adjustment for exposure
during the other time periods. Cases and controls were accrued from 1 January 1981 through 30 June 1995
NSAIDs
Period (Average Cases Controls RRb 95% Cl
before daily n = n =
diagnosis dosea) 5882 23 517
1–6 months 0 3896 15961 1.00 Referent
0<Spi≤0.1 321 1269 1.04 0.91–1.18
0.1<Spi≤0.3 433 1532 1.11 0.98–1.25
Spi>0.3 449 1625 1.05 0.91–1.23
P (trend) 0.20
Otherc 783 3130 – –
7–12 months 0 3873 15912 1.00 Referent
0<Spi≤0.1 305 1272 0.99 0.87–1.13
0.1<Spi≤0.3 435 1456 1.23 1.09–1.39
Spi>0.3 457 1632 1.20 1.02–1.40
P (trend) 0.003
Otherc 812 3245 – –
2–5 years 0 1522 5954 1.00 Referent
0<Spi≤0.1 1277 5240 0.93 0.85–1.01
0.1<Spi≤0.3 311 1183 0.91 0.79–1.06
Spi>0.3 197 848 0.76 0.63–0.92
P(trend) 0.003
Otherc 2575 10292 – –
6–10 years 0 1103 4505 1.00 Referent
0<Spi≤0.1 1201 4858 1.01 0.92–1.11
0.1<Spi≤0.3 235 912 1.03 0.87–1.21
Spi>0.3 144 502 1.13 0.92–1.39
P (trend) 0.35
Other 3199 12740 1.16 0.92–1.48
11–15 years 0 938 3649 1.00 Referent
0<Spi≤0.1 903 3793 0.91 0.82–1.01
0.1<Spi≤0.3 156 553 1.03 0.84–1.25
Spi>0.3 65 280 0.83 0.63–1.11
P (trend) 0.20
Other 3820 15242 1.00 0.81–1.24
a See Methods. ‘Other’ designates the subjects with incomplete or missing exposure data for the period. bRRs were calculated
with conditional logistic regression because of matching for age and index date. cRRs for this category for these periods were
not estimated because of insufficient variation: since cases and controls were matched for index date, if exposure was missing
for a case, due to the 1.5 year gap in the exposure histories beginning 1 July 1987, it was always missing for the matched
controls, so they were all classified as ‘other’ and contributed no information to the matched analysis.stage 2 data were reported only in the final analyses, because
matrix calculations were required (Cain and Breslow, 1988). We
used P < 0.05 (two-sided) as the criterion of statistical signifi-
cance.
Confounder selection strategy
Confounders were selected using a strategy with both forward and
backward components, decided upon a priori to avoid overadjust-
ment (Day et al, 1980). Any variable representing a determinant of
breast cancer whose inclusion in or deletion from a logistic model
resulted in a 10% change in a RR associated with NSAID exposure
was selected as a confounder (Mickey and Greenland, 1989). All
RRs were adjusted for age.
RESULTS
We accrued 5882 breast cancer cases and 23 517 controls. The
cases’ mean age at diagnosis was 64.1 years (13.3 s.d.).
Table 1 shows an analysis in which NSAID exposure was
expressed as Spi for each period, controlling for exposure during
the others. It included all subjects accrued from 1981 to 1995.
Splitting the data into two groups by age at diagnosis (≤ 50 vs > 50
years) provided no evidence for effect modification by age at
diagnosis (P-value for interaction = 0.82).
A protopathic bias was considered as an explanation for the
trend towards increasing RRs associated with increasing NSAID
exposure 7–12 months before the index date: pain from undiag-
nosed metastatic cancer might have resulted in NSAID exposure.
The analysis of Table 1 was repeated, restricting it to cases without
distant metastases at diagnosis, with almost identical results,
suggesting that a protopathic bias was not involved.
Women with pain from any cause may have been examined,
have had breast masses detected, and have received prescriptions
for NSAIDs, producing a positive association between the
dispensing of NSAIDs and the subsequent diagnosis of breast
cancer. The analysis of Table 1 was repeated, restricting it to cases
with tumours > 2 cm diameter at diagnosis, removing those with
tumours more likely to have been detected by physicians’ exami-
nations and screening mammography. The RRs were very similar
to those of Table 1, except for those for the two highest exposure
levels 7–12 months earlier: they were reduced from 1.23 to 1.12
(95% CI 0.93–1.36) for 0.1<Spi≤0.3, and from 1.20 to 1.14 (95%
CI 0.90–1.44) for Spi>0.3, consistent with a detection bias.
To determine whether the trend towards decreasing RRs associ-
ated with increasing NSAID exposure 2–5 years earlier could be
attributed to the effects of determinants of breast cancer associated
with NSAID use, information on potential confounders was
obtained by interviewing samples of subjects accrued from 30
June 1991 to 30 June 1995, selected according to both disease and
exposure status.
Analyses like that of Table 1 were carried out using the data
from the recently accrued stage 1 and stage 2 subjects (Sharpe,
1999). Of the stage 2 subjects 90.9% were post-menopausal on the
index date, 6.0% were premenopausal, and 3.1% were of unknown
menopausal status. The results of both analyses were adjusted only
for age, exposure during the other time periods, and the sampling
fractions. The results pertaining to stage 1 were similar to those of
the overall analysis (Table 1). The results for stage 2 were also
similar. However, the RRs associated with increasing exposure
1–6 months earlier ranged from 0.71–0.83, whereas the corre-
sponding RRs for stage 1 ranged from 1.03–1.13. These differ-
ences could have been due to sampling error, to selection bias
related to non-response, or both.
Consideration of selection bias was simplified because we knew
NSAID exposure status, disease status and age for all subjects. We
could examine the relationship between exposure and disease
among all subjects and among subsets: those selected for inter-
views, those interviewed, and those who were not interviewed. We
concluded that selection bias related to non-response was greatest
for exposure during the 6-month period preceding the index date,
and minimal in relation to earlier exposures (Sharpe, 1999).
To study confounding by drugs associated with breast cancer
development we used data from the SPDP: there was no
confounding by oral contraceptives, corticosteroids, or oestrogens.
Nor was there confounding by the use of ibuprofen and aspirin
bought over the counter, tobacco, alcohol, a positive family history
of breast cancer among first-degree female relatives, the number
of breast biopsies that resulted in benign diagnoses, educational
attainment, age at menarche, age at first birth, height, body mass
index (BMI) before menopause, or age at menopause.
However, the total duration of lactation and BMI after
menopause were confounders. Table 2 juxtaposes the results of the
stage 2 analysis without and with adjustment for these variables.
Despite the wide 95% CIs and the large P-values for trend, Table 2
indicates the direction and magnitude of the confounding. The
adjustment decreased the RRs associated with NSAID exposure
2–5 years earlier, whereas the RRs associated with the highest
levels of exposure 6–10 and 11–15 years earlier became closer to
the null.
In the remaining analyses, we studied the relationships between
NSAID exposure and attributes of the cases’ tumours at diagnosis.
We calculated ORs for tumour diameter > 5 cm diameter or
tumour with direct extension to the chest wall or skin, including
inflammatory carcinoma; these were designated as ‘large’
tumours. We adjusted simultaneously for exposure during all the
time periods, age, and year of diagnosis. Table 3 (left panel) shows
trends towards a decreasing OR for a large tumour associated with
increasing NSAID exposure 2–5 and 6–10 years before diagnosis
(P-trend = 0.056 and 0.02 respectively).
A similar analysis to determine the OR for breast cancer ≤ 2c m
diameter according to NSAID exposure found no trends.
Regional lymph node involvement by tumour at diagnosis was
unassociated with NSAID exposure.
Table 3 (right panel) shows there was a trend towards an
increasing OR for distant metastasis at diagnosis associated with
increasing NSAID exposure 1–6 months before diagnosis (P-
trend = 0.0001), whereas NSAID exposure 2–5 and 6–10 years
before diagnosis was associated with trends towards decreasing
ORs for distant metastasis at diagnosis (P-trend = 0.0003 and 0.03
respectively).
The increasing trend associated with NSAID exposure 1–6
months before diagnosis may have been to a protopathic bias, a
detection bias, or both. The analysis was repeated after excluding
the cases with primary tumours ≤ 2 cm diameter or unknown: the
tumours most likely detected by systematic clinical examinations
or by mammographic screening, which might be carried out more
frequently among NSAID users. The results were very similar,
suggesting that the trend was not due to a detection bias, leaving a
protopathic bias as a possible explanation.
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ated with increasing NSAID exposure 2–5 and 6–10 years before
diagnosis might be explained if NSAID users tended to be exam-
ined more regularly or receive mammography more frequently and
have their primary tumours detected at a smaller size. However, as
noted above, there was no association between NSAID exposure
and having a primary tumour ≤ 2 cm diameter at diagnosis. In
addition, deleting the subjects with tumours ≤ 2 cm diameter from
the analysis did not remove the protective effect associated with
increasing NSAID exposure 2–5 years before diagnosis (P-trend =
0.02). Finally, we repeated the analysis, controlling also for
tumour size (≤ 2 cm diameter, 2–5 cm, > 5 cm or with extension).
The protective effect associated with NSAID exposure 2–5 years
before diagnosis remained, but the protective effect associated
with exposure 6–10 years before diagnosis was no longer evident.
Screening mammography was introduced to Saskatchewan in
1990. Table 4 shows that there were trends towards decreasing rela-
tive odds of being diagnosed with a large tumour or with distant
metastasis over time, after adjustment for age at diagnosis; P-
trend = 0.004 and 0.052 respectively. These trends could have been
due to earlier detection of breast cancer. However, after additional
adjustment for NSAID use, the trends towards decreasing relative
odds of being diagnosed with a large tumour or with distant metas-
tasis over time were no longer evident; P-trend = 0.55 and 0.47
respectively. The ORs adjusted for NSAID use were derived from
the analyses shown in Table 3, which show that NSAID exposure
accounted for the relative odds of being diagnosed with a large
tumour or with distant metastasis better than year of diagnosis.
DISCUSSION
Summary of findings
Increasing NSAID exposure was associated with an increasing RR
for breast cancer 7–12 months later, which was attenuated by
deleting the cases with the smallest tumours, consistent with a
detection bias, rather than a true increase in risk. It was also asso-
ciated with a decreasing RR for breast cancer 2–5 years later
(Table 1), which could not be attributed to confounding by other
determinants of breast cancer (Table 2).
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Table 2 RRs of breast cancer according to NSAID exposure by time period before diagnosis for the stage 2 cases and controls (telephone interview
respondents, accrued from 30 June 1991 through 30 June 1995). The RRs and the 95% Cls have been corrected for the sampling on both disease and
exposure status. Exposure levels were imputed for those cases and controls whose exposure histories during the periods 2–5 and 6–10 years before the index
date were interrupted by the 1.5-year gap in the records of the Prescription Drug Program database. As a result, the true 95% Cls are wider than those shown.
The ‘other’ category of exposure, reserved for subjects with incomplete or missing exposure data, included some subjects during the period 11–15 years before
the index date because of the dates upon which they entered the source population
NSAIDs Stage 2 Crude Adjusted
Period (Average Cases Controls RRa 95% Cl RRb 95% Cl
before daily
diagnosis dose) n = 308 n = 309
1–6 months 0 226 231 1.00 Referent 1.00 Referent
0<Spi≤0.1 8 11 0.75 0.45–1.25 0.75 0.42–1.31
0.1<Spi≤0.3 28 26 0.74 0.44–1.26 0.74 0.43–1.28
Spi>0.3 46 41 0.84 0.44–1.62 0.81 0.42–1.58
P (trend) 0.54
Other 0 0 – – – –
7–12 months 0 213 225 1.00 Referent 1.00 Referent
0<Spi≤0.1 13 9 1.09 0.63–1.90 0.95 0.52–1.73
0.1<Spi≤0.3 30 31 1.12 0.64–1.96 1.15 0.64–2.07
Spi>0.3 52 44 1.26 0.61–2.60 1.26 0.60–2.63
P (trend) 0.52
Other 0 0 – – – –
2–5 years 0 160 178 1.00 Referent 1.00 Referent
0<Spi≤0.1 47 42 0.79 0.47–1.32 0.75 0.44–1.28
0.1<Spi≤0.3 45 37 0.85 0.46–1.57 0.80 0.42–1.52
Spi>0.3 56 52 0.87 0.41–1.83 0.82 0.38–1.77
P (trend) 0.89
Other 0 0 – – – –
6–10 years 0 149 167 1.00 Referent 1.00 Referent
0<Spi≤0.1 49 58 0.95 0.59–1.54 0.88 0.53–1.46
0.1<Spi>0.3 56 41 1.08 0.62–1.87 1.00 0.56–1.78
Spi≤0.3 54 43 1.27 0.65–2.49 1.06 0.52–2.14
P (trend) 0.56
Other 0 0 – – – –
11–15 years 0 155 172 1.00 Referent 1.00 Referent
0<Spi≤0.1 79 67 0.77 0.50–1.21 0.80 0.50–1.27
0.1<Spi>0.3 42 40 0.87 0.53–1.43 0.92 0.55–1.53
Spi≤0.3 18 20 0.58 0.30–1.11 0.72 0.37–1.42
P (trend) 0.58
Other 14 10 1.09 0.75–1.59 1.03 0.68–1.54
aRRs adjusted for the sampling fractions, age and exposure during the other periods. bRRs adjusted for the sampling fractions, age, exposure during the other
periods, total duration of lactation and BMI after menopause.Increasing NSAID exposure was associated with a trend
towards increasing ORs 1–6 months later for distant metastasis at
diagnosis, probably due to a protopathic bias. However, it was also
associated with trends towards decreasing ORs 2–5 and 6–10 years
later for a ‘large’ breast cancer at diagnosis and for distant metas-
tasis. NSAID exposure was unassociated with regional lymph
node involvement.
Representation of exposure
We represented exposure to NSAIDs as a class on the assumption
that all NSAIDs have similar effects on the risk of breast cancer,
since they all reduce prostaglandin synthesis by inhibiting
cyclooxygenase (COX). However, COX exists as two isoenzymes:
COX-1 is present in all cells, whereas COX-2 is induced by stimuli
that provoke inflammation and by tumour promoters (Taketo,
1998). Although currently used NSAIDs inhibit both isoenzymes
to varying extents, it is still unclear which is involved in tumouri-
genesis – COX-1, COX-2, or both. If one isoenzyme is more
involved in tumourigenesis than the other, by analysing the effects
of NSAIDs as a class any protective effects observed will be less
extreme than the true effect of the most potent agent. Although
COX-2 is induced in some breast cancers (Hwang et al, 1998),
NSAIDs may have protective effects unrelated to COX inhibition
(Thompson et al, 1995).
Since our measures of exposure were based on outpatient
prescriptions, subjects’ actual consumption of NSAIDs may have
differed from our estimates. It is unlikely that all the drugs
dispensed were ingested: we may have overestimated exposure.
Alternatively, we may have underestimated exposure, since we
had no information about NSAIDs dispensed in hospitals or as
samples in physicians’ offices. These amounts were probably
small relative to the amounts we used in calculating exposure. The
amounts of aspirin and ibuprofen bought over the counter were
relatively small (Sharpe, 1999), and did not confound the effects of
NSAIDs dispensed under the SPDP. However, subjects in the
reference categories may have had low levels of exposure to either
aspirin or ibuprofen or both.
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Table 3 ORs for tumour size > 5 cm diameter or tumour with direct extension to the chest wall or skin (‘large’), including inflammatory carcinoma, at diagnosis
(left panel), and ORs for distant metastasis at diagnosis of breast cancer (‘Mets (+)’) (right panel), according to NSAID exposure by time period before
diagnosis. The ‘other’ category was for subjects with incomplete or missing exposure information
NSAIDs Tumour sizea Distant metastasisb
Period (Average Large Small ORc 95% Cl Mets Mets ORc 95% Cl
before daily n = 639 n = 4968 (+) (–)
diagnosis dose) n = 364 n = 5370
1–6 months 0 446 3273 1.00 Referent 204 3599 1.00 Referent
0<Spi≤0.1 30 271 0.89 0.60–1.34 23 289 1.61 1.01–2.57
0.1<Spi≤0.3 34 376 0.79 0.53–1.17 41 379 2.50 1.69–3.71
Spi>0.3 44 381 0.99 0.62–1.57 39 395 2.79 1.68–4.64
P (trend) 0.64 0.0001
Other 85 667 0.91 0.63–1.32 57 708 1.12 0.71–1.76
7–12 months 0 449 3235 1.00 Referent 225 3550 1.00 Referent
0<Spi≤0.1 31 263 0.95 0.63–1.41 22 277 1.15 0.71–1.86
0.1<Spi≤0.3 30 381 0.64 0.42–0.98 24 400 0.67 0.41–1.10
Spi>0.3 44 391 0.84 0.51–1.37 30 411 0.62 0.35–1.12
P (trend) 0.32 0.10
Other 85 698 0.95 0.65–1.39 63 732 1.17 0.73–1.86
2–5 years 0 212 1217 1.00 Referent 120 1364 1.00 Referent
0<Spi≤0.1 128 1075 0.74 0.58–0.94 60 1174 0.52 0.37–0.73
0.1<Spi≤0.3 30 269 0.75 0.48–1.15 18 287 0.53 0.30–0.92
Spi>0.3 21 165 0.83 0.47–1.46 12 181 0.49 0.24–0.99
P (trend) 0.06 0.0003
Other 248 2242 0.69 0.54–0.90 154 2364 0.66 0.48–0.92
6–10 years 0 147 898 1.00 Referent 86 991 1.00 Referent
0<Spi≤0.1 101 1052 0.62 0.47–0.82 69 1109 0.74 0.53–1.04
0.1<Spi≤0.3 20 208 0.61 0.37–1.01 11 220 0.47 0.24–0.92
Spi>0.3 16 118 0.84 0.47–1.50 10 127 0.74 0.36–1.51
P (trend) 0.02 0.03
Other 355 2692 0.73 0.52–1.02 188 2923 0.88 0.57–1.34
11–15 years 0 98 807 1.00 Referent 57 859 1.00 Referent
0<Spi≤0.1 83 795 0.92 0.68–1.26 34 846 0.62 0.40–0.96
0.1<Spi≤0.3 16 132 1.05 0.59–1.88 9 139 0.83 0.40–1.76
Spi>0.3 5 56 0.67 0.25–1.75 5 58 1.03 0.38–2.74
P (trend) 0.63 0.36
Other 437 3178 1.02 0.54–1.94 259 3468 1.19 0.55–2.60
a 5,607 cases were included in this analysis; 275 cases were excluded because of missing tumour size information. b 5,734 cases were included in this analysis;
148 cases were excluded because of missing information regarding distant metastases. c ORs were calculated with unconditional logistic regression with
adjustment for exposure during the other time periods, age at diagnosis, and year of diagnosis.If we overestimated NSAID exposure among those subjects
classified as highly exposed and underestimated NSAID exposure
among those subjects classified as unexposed, then the slopes of
the dose–risk relationships that we observed would be less
extreme than the true slope (MacMahon and Trichopoulos, 1996).
However, the most highly exposed subjects may have ingested
almost all of the NSAIDs dispensed, if they suffered chronic pain.
If we accurately estimated overall NSAID exposure among the
highly exposed and underestimated it among the nonexposed, then
the true dose–risk curves would be shifted to the right relative to
what we observed with increased slopes.
Other potential confounders
Could there have been confounding by other known determinants
of breast cancer that we did not measure?
We did not collect information on subjects’ indications for
NSAID use, because no associations have been reported with
breast cancer. However, heavy users of NSAIDs with chronic
arthritis could have been less physically active than those less
highly exposed. Although physical activity has been associated
with protective effects (Thune et al, 1997), we did not measure it
because it is not yet clear that the protective effects are due to
physical activity per se rather than uncontrolled confounding or
recall bias (Gammon et al, 1998). If physical activity is protective
and if the heaviest users of NSAIDs were physically inactive, then
they would have been at higher risk of developing breast cancer.
The true protective effects of NSAID exposure on risk may be
more extreme than those we observed.
Our analyses of the effects of NSAID exposure on stage could
be confounded by other determinants of tumour stage associated
with NSAID exposure. Since lower socioeconomic status and
obesity tend to be associated with both NSAID exposure (Sharpe,
1999) and with higher stage at diagnosis (Richardson et al, 1992;
Hunter et al, 1993), these variables may have been confounders. If
NSAID users were at increased risk of presenting with higher
stage disease, then the true protective effects of NSAIDs against
large tumour size and distant metastasis may be more extreme than
we observed.
Interpretation of results
It is unlikely that the dose-dependent reduction in the RR for
breast cancer associated with NSAID exposure 2–5 years earlier
was due to chance (Table 1). Selection or recall bias were unlikely
due to the study design. If the pattern of confounding among the
subjects in the overall analysis (Table 1) was similar to that
observed among the stage 2 subjects (Table 2), then this protective
effect of NSAID exposure cannot be attributed to confounding. A
biologic explanation is called for.
Walter and Day (1983) estimated the duration of the detectable
preclinical phase of breast cancers with data from a mammo-
graphic screening trial. Their results suggest that 5–56% of our
cases had already developed mammographically detectable breast
cancers during the period 2–5 years before the index date, if one
assumes that the source population was not systematically
screened. However, the introduction of mammographic screening
to Saskatchewan began in 1990, so this estimate may be high.
Nevertheless, it is unlikely that NSAIDs prevent breast cancer
from developing de novo, since time must elapse between tumour
initiation and mammographic detectability. NSAIDs may slow the
growth of tumours, reducing the probability of detection on the
index date; i.e. postponing it.
Experimental results support this conclusion. Lala et al (1997)
found that the oral administration of indomethacin to a strain of
mice, 90% of which develop spontaneous mammary carcinomas,
delayed the appearance of the first tumours by 11–12 weeks. The
tumours of the treated mice showed increased cell death and
reduced vascularity. Robertson et al (1998) administered ibuprofen
to rats that developed mammary carcinomas after receiving a
carcinogen 100 days earlier. After 35 days of ibuprofen, the tumour
volumes of the treated animals had decreased, whereas those of the
controls had increased, showing that NSAIDs can reverse the
growth of established mammary carcinomas.
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Table 4 ORs for tumour size and for distant metastasis according to year of diagnosis, with adjustment for age at
diagnosis, or for age at diagnosis and NSAID exposure as represented in Table 3. ‘Large’ indicates tumour size > 5 cm
diameter or tumour with direct extension to the chest wall or skin, including inflammatory carcinoma. The ORs and their
95% Cls in the two columns on the right side of the table were derived from the analyses shown in Table 3
Year of Large Small Adjusted for age
diagnosis n = n = Adjusted for age and NSAID Use
639 4968 ORa 95% Cl ORa 95% Cl
1981–1985 203 1363 1.00 Referent 1.00 Referent
1986–1990 222 1701 0.86 0.70–1.06 0.92 0.64–1.33
1991–1995 214 1904 0.74 0.60–0.90 0.86 0.46–1.63
P (trend) 0.004 0.55
Mets Mets
(+) (–)
n = n =
364 5370
1981–1985 106 1517 1.00 Referent 1.00 Referent
1986–1990 145 1830 1.09 0.84–1.42 1.17 0.73–1.88
1991–1995 113 2023 0.77 0.59–1.02 1.22 0.56–2.66
P (trend) 0.052 0.47
a Calculated with unconditional logistic regression.Effects of NSAIDs on breast cancer risk and stage 119
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The magnitude of the protective effect on risk that we observed
at the highest level of exposure (Table 1, RR = 0.76, 95% CI
0.63–0.92) was comparable to that observed by others (Gridley et
al, 1993; Schreinemachers and Everson, 1994; Friedman and Ury,
1980; Harris et al, 1995, 1996). However, some did not find
similar effects. Some studies used only limited exposure data
(Isömaki et al, 1978; Thun et al, 1993). All failed to deal with the
timing of exposure, which might explain why Egan et al (1996)
found that aspirin had no effect.
The fact that the protective effects of NSAIDs on incidence,
tumour size and risk of distant metastasis were all associated with
exposure 2–5 years before diagnosis suggests that NSAIDs may
have interfered with aspects of tumour development which
occurred during that period.
NSAIDs could slow or reverse the growth of both primary
tumours and distant metastases by promoting apoptosis (Han et al,
1998; Lala et al, 1997) and inhibiting angiogenesis (Ziche et al,
1982; Hudson et al, 1995; Lala et al, 1997). For example,
indomethacin treatment reduced the incidence of macroscopic
metastatic lung nodules that developed in athymic nude mice after
subcutaneous transplantation of a human breast cancer cell line,
but had no effect on the incidence of micrometastases.
Indomethacin may have interfered with the phase of tumour
growth dependent on angiogenesis and prevented micrometastases
from becoming macroscopic (Connolly et al, 1996).
The onset of tumour neovascularization coincides with the
spread of tumour cells into the circulation and the development of
distant metastases (Folkman, 1995). These processes require
tumour cells to invade the vascular endothelium on entering and
leaving the circulation. NSAIDs may interfere with this process in
vivo, because in vitro indomethacin suppresses the invasion of
human breast cancer cells through a reconstituted basement
membrane (Connolly and Rose, 1993).
NSAIDs may have had no effect on the spread of breast cancer
to the regional lymph nodes because angiogenesis and vascular
invasion were not involved in its occurrence.
CONCLUSION
The magnitude of the protective effects associated with NSAID
exposure that occur 2–5 years later, the existence of dose–risk rela-
tionships, and the coherence of these results with the experimental
evidence strongly suggest that NSAIDs may slow the growth of
established but undiagnosed breast cancers and reduce the risk of
distant metastasis at diagnosis.
Although trials of chemoprevention by NSAIDs are being advo-
cated against breast cancer (Vainio and Morgan, 1998), our inter-
pretation suggests that trials involving women screened at entry
might not demonstrate protective effects. NSAIDs may have more
potential as therapeutic agents than as preventive agents: they may
be useful in delaying or preventing the appearance of distant
metastases after diagnosis.
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